Fulgent Genetics, Inc. (NASDAQ:FLGT) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. lessened its holdings in shares of Fulgent Genetics, Inc. (NASDAQ:FLGTFree Report) by 0.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 116,273 shares of the company’s stock after selling 1,088 shares during the quarter. Principal Financial Group Inc. owned approximately 0.39% of Fulgent Genetics worth $3,109,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in FLGT. Price T Rowe Associates Inc. MD grew its stake in shares of Fulgent Genetics by 4.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,947 shares of the company’s stock valued at $207,000 after acquiring an additional 316 shares in the last quarter. Commonwealth Equity Services LLC grew its stake in Fulgent Genetics by 2.4% in the first quarter. Commonwealth Equity Services LLC now owns 14,988 shares of the company’s stock worth $467,000 after purchasing an additional 353 shares in the last quarter. Teachers Retirement System of The State of Kentucky grew its stake in Fulgent Genetics by 5.9% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 6,421 shares of the company’s stock worth $238,000 after purchasing an additional 355 shares in the last quarter. Geneos Wealth Management Inc. grew its stake in Fulgent Genetics by 416.8% in the first quarter. Geneos Wealth Management Inc. now owns 491 shares of the company’s stock worth $30,000 after purchasing an additional 396 shares in the last quarter. Finally, Covington Capital Management grew its stake in Fulgent Genetics by 133.3% in the third quarter. Covington Capital Management now owns 700 shares of the company’s stock worth $27,000 after purchasing an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 46.09% of the company’s stock.

Insider Buying and Selling

In related news, COO Jian Xie sold 1,617 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $27.25, for a total transaction of $44,063.25. Following the sale, the chief operating officer now owns 386,903 shares of the company’s stock, valued at $10,543,106.75. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Fulgent Genetics news, CFO Paul Kim sold 1,307 shares of Fulgent Genetics stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $27.25, for a total value of $35,615.75. Following the transaction, the chief financial officer now owns 201,897 shares in the company, valued at $5,501,693.25. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, COO Jian Xie sold 1,617 shares of Fulgent Genetics stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $27.25, for a total transaction of $44,063.25. Following the transaction, the chief operating officer now owns 386,903 shares in the company, valued at $10,543,106.75. The disclosure for this sale can be found here. Insiders have sold a total of 28,140 shares of company stock valued at $751,784 over the last quarter. Corporate insiders own 31.76% of the company’s stock.

Fulgent Genetics Price Performance

Shares of NASDAQ:FLGT opened at $25.27 on Friday. Fulgent Genetics, Inc. has a 12 month low of $23.09 and a 12 month high of $44.09. The stock has a market cap of $748.75 million, a price-to-earnings ratio of -11.81 and a beta of 1.50. The stock’s 50 day moving average price is $27.38 and its 200 day moving average price is $28.92.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Piper Sandler cut their target price on shares of Fulgent Genetics from $37.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, October 16th. TheStreet cut Fulgent Genetics from a “c-” rating to a “d+” rating in a report on Friday, November 3rd. Finally, UBS Group initiated coverage on Fulgent Genetics in a report on Thursday, December 7th. They set a “neutral” rating and a $35.00 price target on the stock. Three research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $36.00.

View Our Latest Research Report on Fulgent Genetics

Fulgent Genetics Company Profile

(Free Report)

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer, cardiovascular genetics, reproductive health, and neurodegenerative genetics, as well as pharmacogenetic tests.

Featured Stories

Want to see what other hedge funds are holding FLGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fulgent Genetics, Inc. (NASDAQ:FLGTFree Report).

Institutional Ownership by Quarter for Fulgent Genetics (NASDAQ:FLGT)

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.